Latest on Pharmaceutical Industry


AstraZeneca ups investment in messenger RNA drugs with Ethris deal

AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros ($29 million) on a research alliance with German biotech start-up Ethris. ..Read More...

New Novartis drug takes aim at tough-to-treat malaria

Novartis is taking aim at drug-resistant malaria – a growing global problem – by launching clinical trials of the first new antimalarial medicine for many years in nine countries across Africa and Asia. The Swiss ..Read More...



CPhI Korea 2017

COEX Hall D, Seoul,


The 4th International Symposium of Materials on Regenerative Medicine (2017 ISOMRM)

Aspire Resort, Taoyuan,
Chung Yuan Christian University

Press Releases

Caret Pharma To Acquire Fiber Choice®

Caret Pharma a subsidiary of Caret Group today announced it has entered into an agreement with Moberg Pharma AB to acquire the assets of Fiber Choice a line of innovative dietary supplements containing 100 natural prebio.. Read More...

BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization

BioLineRx Ltd a clinicalstage biopharmaceutical company focused on oncology and immunology announced today the filing of regulatory submissions required to commence a randomized controlled Phase 3 registrational trial of.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics